SCHEMBL21595501

SCHEMBL21595501

CCOc1ccc(C(=S)Nc2ccccc2F)nc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 2/20 0.43
P4HTM Q9NXG6 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HPGD P15428 2/20 0.41
PKM P14618 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30763008 1.00 ALDH1A1 (0.56) ALDH1A1NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL30763190 0.86 SMN1; SMN2 (0.60) ALDH1A1NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL21595582 0.86 SMN1; SMN2 (0.60) ALDH1A1NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL21595575 0.85 ALDH1A1 (0.43) ALDH1A1NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL30763078 0.85 ALDH1A1 (0.43) ALDH1A1NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL20302473 0.85 RAB9A (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL30763073 0.85 RAB9A (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL21595542 0.84 ALDH1A1 (0.43) ALDH1A1NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL21595585 0.84 SMN1; SMN2 (0.44) ALDH1A1NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL30763109 0.84 SMN1; SMN2 (0.44) ALDH1A1NPC1RAB9AL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810597-B1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS UNIV OSLO HF (NO) 2025-11-26 EP disclosed
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors OSLO UNIVERSITETSSYKEHUS HF (NO) 2024-03-12 US disclosed
CN-112469714-B 1,2, 4-triazole derivatives as tankyrase inhibitors 奥斯陆大学国家医院 2024-03-01 CN disclosed
EP-3810597-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS Oslo Universitetssykehus HF (NO) 2021-04-28 EP disclosed
CN-112469714-A 1,2, 4-triazole derivatives as tankyrase inhibitors 奥斯陆大学国家医院 2021-03-09 CN disclosed
WO-2019243822-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS OSLO UNIVERSITETSSYKEHUS HF (NO) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors GBA3, CBR3, TECR ALDH1A1 2191/4885NPC1 1998/4885RAB9A 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.